userPhoto

Dr. Barry Springer

Position
Vice President Strategy, Innovation and Research
Location
Spring House PA UNITED STATES
Bio

Barry A. Springer, Ph.D., Vice President Strategy, Innovation and Research, Janssen BioTherapeutics (JBIO), Janssen R&D, Pharmaceutical companies of Johnson & Johnson earned a Ph.D. in Biochemistry from the University of Illinois and completed postdoctoral training as a Helen Hay Whitney Fellow at U.C. Berkeley. Dr. Springer has over 23 years of professional leadership experience shared between large pharma and small biotech environments in both small molecule and biologics drug discovery and development, and technology licensing and development. In his current role he is responsible for leading Janssen BioTherapeutics’ (formerly Centocor) technology, strategy and operations initiatives including leading external scientific and business partnering activities. Dr. Springer is responsible for establishing the strategy and managing biologics-based partnerships with the newly formed J&J Innovation Centers and he also leads the Janssen R&D cross function integrated technology strategy that seeks to identify and fund new innovative technologies of high strategic value. Dr. Springer started his professional career at DuPont Merck and moved to 3-Dimensional Pharmaceuticals (3DP) as a founding member of the technology-based biotech company. During his tenure there he established innovative technology platforms for lead generation, Gene to Protein, HTS and Structural Biology. He established and led numerous teams while at 3DP including lead generation which produced several molecules that entered clinical development. Dr. Springer was also successfully awarded numerous grants from SBIR NIH and NIST focused on protein engineering of growth factors and GPCRs. He was also involved business development initiatives one of which led to the acquisition of 3DP by J&J. Following the acquisition of 3DP by J&J Dr. Springer was V.P. of Enabling Technologies where he established and led all of the technology platform efforts, and as a member of the Spring House Research and Development leadership team contributed to the successful early development and POC of Invokana. He moved to the JBIO in 2011 where he led the in-licensing of the DuoBody mAb platform from Genmab. Dr. Springer has over 40 peer reviewed publications and over 25 issued patents.

Sessions/Events
BiotherapeuticDelivery_icon
Add to myBIO Planner Notes
BiotherapeuticDelivery_icon
Add to myBIO Planner Notes
BiotherapeuticDelivery_icon
Add to myBIO Planner Notes